The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).
This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.
Ionis Pharmaceuticals (IONS) is the sponsoring company for this trial. BiotechSign currently grades this company C (55/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.